[go: up one dir, main page]

HRP20041108B1 - Peptidi povezani sa tumorom koji se vežu na mhc molekule - Google Patents

Peptidi povezani sa tumorom koji se vežu na mhc molekule

Info

Publication number
HRP20041108B1
HRP20041108B1 HRP20041108AA HRP20041108A HRP20041108B1 HR P20041108 B1 HRP20041108 B1 HR P20041108B1 HR P20041108A A HRP20041108A A HR P20041108AA HR P20041108 A HRP20041108 A HR P20041108A HR P20041108 B1 HRP20041108 B1 HR P20041108B1
Authority
HR
Croatia
Prior art keywords
tumor
bond
mhc molecules
relates
peptide
Prior art date
Application number
HRP20041108AA
Other languages
English (en)
Inventor
Toni Weinschenk
Hans Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HRP20041108A2 publication Critical patent/HRP20041108A2/hr
Publication of HRP20041108B1 publication Critical patent/HRP20041108B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)

Abstract

Izum se odnosi na peptid povezan s tumorom koji sadrži aminokiselinski slijed koji se odabire iz skupine koja se sastoji od SEQ ID br. 1 do SEQ iD br. 79 ograđenog protokola. Peptid ima sposobnost vezati se na molekulu humanog glavnog kompleksa histokompatibilnosti (MHC) skupine I. Izum se također odnosi na upotrebu peptida u proizvodnji lijeka za liječenje tumorskih bolesti. Izum se također odnosi i na farmaceutski pripravak koji obuhvaća najmanje jedan od navedenih peptida.
HRP20041108AA 2002-05-29 2003-03-27 Peptidi povezani sa tumorom koji se vežu na mhc molekule HRP20041108B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225144A DE10225144A1 (de) 2002-05-29 2002-05-29 An MHC-Moleküle bindende Tumor-assoziierte Peptide
PCT/EP2003/003181 WO2003102023A1 (de) 2002-05-29 2003-03-27 An mhc-moleküle bindende tumor-assoziierte peptide

Publications (2)

Publication Number Publication Date
HRP20041108A2 HRP20041108A2 (en) 2005-10-31
HRP20041108B1 true HRP20041108B1 (hr) 2013-11-08

Family

ID=29557592

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20041108AA HRP20041108B1 (hr) 2002-05-29 2003-03-27 Peptidi povezani sa tumorom koji se vežu na mhc molekule

Country Status (15)

Country Link
US (5) US7396904B2 (hr)
EP (5) EP1734049B1 (hr)
JP (5) JP4472520B2 (hr)
AT (5) ATE466872T1 (hr)
AU (2) AU2003224001B2 (hr)
CA (5) CA2487137C (hr)
CY (5) CY1108507T1 (hr)
DE (6) DE10225144A1 (hr)
DK (5) DK1507795T3 (hr)
ES (5) ES2350461T3 (hr)
HR (1) HRP20041108B1 (hr)
PL (5) PL206306B1 (hr)
PT (5) PT1734048E (hr)
SI (5) SI1507795T1 (hr)
WO (1) WO2003102023A1 (hr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20050221350A1 (en) 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
EP2857035B1 (en) * 2003-01-30 2017-11-29 Survac ApS Survivin-derived peptides and use thereof
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
KR101176673B1 (ko) * 2003-12-01 2012-08-23 가부시키가이샤 메이지 앤지오텐신 변환 효소 저해 팹티드
EP1695089A1 (en) * 2003-12-15 2006-08-30 Aurelium Biopharma Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
DE102004011503A1 (de) * 2004-01-28 2005-09-15 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung und Quantifizierung von tumor-assoziierten Peptiden
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
ES2319286T3 (es) * 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
ES2689851T3 (es) * 2007-07-27 2018-11-16 Immatics Biotechnologies Gmbh Nuevos epítopos inmunogénicos para inmunoterapia
WO2009129498A2 (en) * 2008-04-17 2009-10-22 Immuneregen Biosciences, Inc. Substance p and analogs thereof as a cancer immunogenic composition adjuvant
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
CN101451975B (zh) * 2008-12-29 2012-01-25 浙江大学 一种检测胃癌预后与分期血清蛋白质的方法
US8075895B2 (en) * 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) * 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions
ES2900004T3 (es) * 2013-08-05 2022-03-15 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
JPWO2015050259A1 (ja) * 2013-10-03 2017-03-09 大日本住友製薬株式会社 腫瘍抗原ペプチド
DK3068428T3 (da) 2013-11-13 2022-10-17 Univ Minnesota Annexin-ii-variant-sammensætninger og fremgangsmåder
ES2952959T3 (es) 2015-03-27 2023-11-07 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra diversos tumores (SEQ ID N.º 25 - MXRA5-003)
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MA42294B1 (fr) 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201520558D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
HRP20210698T1 (hr) 2015-12-22 2021-09-17 Immatics Biotechnologies Gmbh Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
KR102184377B1 (ko) 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
WO2019160383A1 (ko) * 2018-02-19 2019-08-22 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
BR102018010523A2 (pt) * 2018-05-23 2020-04-28 Univ Estadual Campinas Unicamp peptídeo, composição farmacêutica compreendendo o mesmo e uso

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739009A (en) * 1996-12-12 1998-04-14 Incyte Pharmaceuticals, Inc. Adipocyte-specific differentiation-related protein
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE19837015C2 (de) * 1998-08-14 2003-03-20 Vasopharm Biotech Gmbh Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1)
DE19936563A1 (de) 1999-08-04 2001-02-08 Boehringer Ingelheim Int Tumorassoziiertes Antigen
US6809179B1 (en) 1999-08-04 2004-10-26 Boehringer Ingelheim International Gmbh Tumor-associated antigen (R11)
AU2001233955A1 (en) * 2000-02-24 2001-09-03 Oxford Glycosciences (Uk) Limited Diagnosis and treatment of bipolar affective disorder
AU2001295582A1 (en) * 2000-12-20 2002-07-01 GlaxoSmithKline Biologicals (s.a.) Tumour-related antigens
US20030170719A1 (en) * 2000-12-28 2003-09-11 Akio Matsuda NF-kappa B activating gene
WO2002086443A2 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US6867283B2 (en) * 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003048323A2 (en) * 2001-12-03 2003-06-12 Bristol-Myers Squibb Company Polynucleotides and polypeptides associated with the development of rheumatoid arthritis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810781A (en) * 1987-01-15 1989-03-07 The George Washington University Methods of preparing epitopes of tumor associated antigens

Also Published As

Publication number Publication date
EP2006294A1 (de) 2008-12-24
PL211158B1 (pl) 2012-04-30
AU2010200689A1 (en) 2010-03-18
EP1734049A1 (de) 2006-12-20
DK1734048T3 (da) 2009-02-23
EP2014673B1 (de) 2010-05-05
ATE478088T1 (de) 2010-09-15
ATE410442T1 (de) 2008-10-15
PL211159B1 (pl) 2012-04-30
US8536304B2 (en) 2013-09-17
CA2487137A1 (en) 2003-12-11
AU2003224001A1 (en) 2003-12-19
PT2006294E (pt) 2010-11-12
JP5042303B2 (ja) 2012-10-03
EP1734048B1 (de) 2008-12-17
EP2006294B1 (de) 2010-08-18
PT1507795E (pt) 2008-12-26
US20080057077A1 (en) 2008-03-06
US20100183644A1 (en) 2010-07-22
JP2010099079A (ja) 2010-05-06
CA2736926C (en) 2015-11-17
EP2014673A1 (de) 2009-01-14
JP5042302B2 (ja) 2012-10-03
SI2006294T1 (sl) 2010-11-30
CA2736926A1 (en) 2003-12-11
SI1734049T1 (sl) 2009-02-28
CY1108507T1 (el) 2014-04-09
ES2317378T3 (es) 2009-04-16
HRP20041108A2 (en) 2005-10-31
JP4472520B2 (ja) 2010-06-02
ATE416188T1 (de) 2008-12-15
ATE417859T1 (de) 2009-01-15
WO2003102023A1 (de) 2003-12-11
DE50310952D1 (de) 2009-01-29
US20080051347A1 (en) 2008-02-28
US20100184211A1 (en) 2010-07-22
AU2010200689B2 (en) 2012-07-12
DE50312701D1 (de) 2010-06-17
CA2487137C (en) 2013-02-19
JP2010099078A (ja) 2010-05-06
DK1734049T3 (da) 2009-01-19
US7763711B2 (en) 2010-07-27
CY1110723T1 (el) 2015-06-10
SI1734048T1 (sl) 2009-02-28
PL211157B1 (pl) 2012-04-30
PL210356B1 (pl) 2012-01-31
JP2006511196A (ja) 2006-04-06
CA2736921C (en) 2013-09-03
DE50313004D1 (de) 2010-09-30
EP1507795A1 (de) 2005-02-23
DK2014673T3 (da) 2010-08-30
CA2736974C (en) 2014-09-02
CY1108680T1 (el) 2014-04-09
ES2314196T3 (es) 2009-03-16
CY1108673T1 (el) 2014-04-09
SI1507795T1 (sl) 2009-04-30
DE50310882D1 (de) 2009-01-15
CA2736972C (en) 2014-08-05
PT1734049E (pt) 2008-12-26
JP5042300B2 (ja) 2012-10-03
AU2003224001B2 (en) 2010-03-11
DK1507795T3 (da) 2008-12-08
DE10225144A1 (de) 2003-12-18
ES2348468T3 (es) 2010-12-07
JP2010099080A (ja) 2010-05-06
PT2014673E (pt) 2010-08-04
PL373700A1 (en) 2005-09-05
PT1734048E (pt) 2009-01-02
CA2736921A1 (en) 2003-12-11
US7396904B2 (en) 2008-07-08
JP5042301B2 (ja) 2012-10-03
US8399613B2 (en) 2013-03-19
EP1507795B1 (de) 2008-10-08
ES2350461T3 (es) 2011-01-24
ATE466872T1 (de) 2010-05-15
CA2736972A1 (en) 2003-12-11
PL206306B1 (pl) 2010-07-30
SI2014673T1 (sl) 2010-09-30
US7666984B2 (en) 2010-02-23
DE50310613D1 (de) 2008-11-20
EP1734049B1 (de) 2008-12-03
EP1734048A1 (de) 2006-12-20
CA2736974A1 (en) 2003-12-11
CY1111174T1 (el) 2015-06-11
US20050222390A1 (en) 2005-10-06
JP2010088449A (ja) 2010-04-22
DK2006294T3 (da) 2010-12-13
ES2317379T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
Michels et al. Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis
RS54215B1 (en) COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
AU2003228962A8 (en) Ferritin fusion proteins for use in vaccines and other applications
CN107075574A (zh) 铁调素和微型铁调素类似物及其用途
GEP20115324B (en) Tweak binding antibodies
TW200744642A (en) Novel peptides for use in the treatment of obesity
DE60222790D1 (de) Dendrimere zur verwendung in gezielter verabreichung
HRP20010877B1 (hr) Pripravci za prevenciju i liječenje amiloidogenskih bolesti
HUP0203506A2 (hu) Terápiás ágensként használható módosított peptidek
NZ592510A (en) HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same
WO2004016643A3 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
MEP57508A (en) Binding agents which inhibit myostatin
RU2011100801A (ru) Конъюгаты для введения биологически активных соединений
JP2011518179A5 (hr)
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
NZ768283A (en) Cpg amphiphiles and uses thereof
DE60138558D1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
WO2006138745A3 (en) Therapeutic peptides and vaccines
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
JP2007506713A (ja) 例えば、抗血管新生活性を有するペプチドおよび治療におけるその適用
JP2019038772A5 (hr)
WO2004085461A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20180319

Year of fee payment: 16

PBON Lapse due to non-payment of renewal fee

Effective date: 20190327